Silence Therapeutics (NASDAQ:SLN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

A number of other research firms have also recently commented on SLN. Chardan Capital reiterated a buy rating and set a $42.00 price target on shares of Silence Therapeutics in a report on Friday, May 17th. Morgan Stanley reiterated an overweight rating and set a $45.00 target price on shares of Silence Therapeutics in a research note on Monday, April 22nd.

Silence Therapeutics Stock Up 3.8 %

SLN stock opened at $19.00 on Thursday. The business has a 50 day moving average of $21.22 and a 200 day moving average of $20.92. Silence Therapeutics has a twelve month low of $4.84 and a twelve month high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.18. The firm had revenue of $15.73 million during the quarter, compared to the consensus estimate of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. As a group, sell-side analysts expect that Silence Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of Silence Therapeutics in the 4th quarter worth $110,000. Vivo Capital LLC purchased a new stake in shares of Silence Therapeutics during the 4th quarter valued at about $8,862,000. Parkman Healthcare Partners LLC increased its position in shares of Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the last quarter. Redmile Group LLC bought a new position in shares of Silence Therapeutics in the 1st quarter worth approximately $43,798,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Silence Therapeutics in the first quarter worth approximately $13,575,000. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.